Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.

Saida, Takahiko; Yokoyama, Kazumasa; Sato, Ryusuke; Makioka, Haruki; Iizuka, Yukihiko; Hase, Masakazu; Ling, Yan; Torii, Shinichi

Saida, Takahiko; Yokoyama, Kazumasa; Sato, Ryusuke; Makioka, Haruki; Iizuka, Yukihiko; Hase, Masakazu; Ling, Yan; Torii, Shinichi.

Affiliation

Saida T; Kansai Multiple Sclerosis Center, Kyoto Min-iren Central Hospital, Kyoto, Japan. saida_takahiko@maia.eonet.ne.jp.
Yokoyama K; Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Sato R; Biogen Japan Ltd., Tokyo, Japan.
Makioka H; Biogen Japan Ltd., Tokyo, Japan.
Iizuka Y; Biogen Japan Ltd., Tokyo, Japan.
Hase M; Biogen Japan Ltd., Tokyo, Japan.
Ling Y; Biogen Japan Ltd., Tokyo, Japan.
Torii S; Biogen Japan Ltd., Tokyo, Japan.

Neurol Ther ; 6(2): 197-211, 2017 Dec.

Article de En | MEDLINE | ID: mdl-29119538

Mots clés

Japan; Multiple sclerosis; Natalizumab; Post-marketing surveillance

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Screening_studies Langue: En Journal: Neurol Ther Année: 2017 Type de document: Article Pays d'affiliation: Japon Pays de publication: Nouvelle-Zélande

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google